Latif Nasser

Leonard Saltz.

I'm a medical oncologist at Memorial Sloan Kettering Cancer Center.

Which is here in New York, and it's one of the largest cancer centers in the country.

I mean, we have 17 doctors here who treat colon cancer.

Just for colon cancer.

We treat a very large number of patients.

It's a huge hospital, and one of the things Leonard's been noticing in the last, I don't know, decade, is cancer drug prices have just gone through the roof.

I mean, we have drugs out there that are many hundreds of dollars per pill.

Really?

Yeah.

Oh, just wait.

Let's see.

Where does this start?

It starts, it's June in 2012.

Leonard Saltz is at a conference, and at this conference is a pharmaceutical company called Sanofi, and they give a presentation about a new drug that they have.

A drug called Zaltrap.

And Zaltrap is a drug that, without getting into the science too much, targets the blood supply to the tumor.

It cuts off the blood supply, which means the tumor can't grow.

That's the scientific hypothesis.

So this new drug is presented and they present the data.